A new study shows that Arc protein in mice facilitates the spread of toxic Tau between neurons via extracellular vesicles, driving Alzheimer’s disease progression.

Removing Arc in mouse models markedly reduces Tau transfer and halts its spread to healthy cells, indicating Arc is a key mediator of intercellular Tau transmission.

Tau tangles released from diseased neurons in association with Arc can seed new Tau aggregates in neighboring neurons, amplifying neurodegeneration.

researchers note the work is preliminary and emphasize that any effective therapies will require extensive validation and safety testing before clinical use.

Disclosures indicate one researcher has ties to biotech companies and licenses Arc-related patents, noted in the report.

Human brain tissue shows EVs containing Arc and Tau, suggesting the mechanism observed in mice may be relevant to people, though validation in humans is needed.

Alzheimer’s patient brain samples reveal Arc and tau co-packaged in extracellular vesicles, implying the mechanism could translate to humans with further research.

The Cell paper published on June 29, 2026 identifies intercepting Tau spread via Arc-containing EVs as a potential new therapeutic avenue for Alzheimer’s.

Blocking Tau spread through Arc-containing EVs could slow cognitive decline in early-stage Alzheimer’s without urgently destroying brain cells.

Proposed therapy focuses on intercepting or neutralizing Tau-containing EVs in the extracellular space, rather than broadly inhibiting Arc, to slow disease progression.

Therapeutic implications center on mid-flight Tau-containing EVs to halt progression, rather than solely preventing Tau release from diseased cells.

Arc has a dual role: it may promote Tau spread but could also help early-stage cells survive by exporting Tau, so blocking Arc could have complex effects.